Elliott buys shares of Endologix

By Lisa Kerner

Charlotte, N.C., April 7 - Endologix, Inc. investors led by Elliott Associates, LP bought 677,500 shares of the company's stock on April 3. Each share was priced at $2.52 or $2.62.

The transactions were reported in a schedule 13D filing with the Securities and Exchange Commission.

Elliott beneficially owns 3,590,796 shares, or 8.4%, of the Irvine, Calif., company that develops minimally invasive treatments for vascular diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.